The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012

Review Committee Recommends Sample Size of 10,900 Patients Based on Interim Analysis PARSIPPANY, NJ, Jul 02, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced it expects to complete patient enrollment of the pivotal Phase 3 CHAMPION PHOENIX trial of cangrelor in fourth quarter of 2012. The Company accepted the recommendation of a […]

The Medicines Company’s Cangrelor Bridge Trial Published in the Journal of the American Medical Association

PARSIPPANY, NJ, Jan 17, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced publication in the Journal of the American Medical Association (JAMA) of clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet. The article, “Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery,” is available in the January 18 […]